Bleeding in cancer: epidemiological aspects
Year: 2026
Type: article
Abstract: Cancer is accompanied with significant changes in hemostasis caused by both the underlying malignancy and its treatment, which increases the risk of thrombotic and bleeding consequences. While cancer-related thrombosis has been extensively studied, bleeding remains relatively unexplored, despite its major contribution to morbidity and mortality in this population. The epidemiology of bleeding in cancer patients is complicated and difficult to assess. Multiple linked factors influence risk, such as tumor kind, disease stage, treatment modalities, patient clinical context, and concomitant diseases. Furthermore, bleeding risk varies over time, reflecting dynamic changes in tumor load, treatment approaches, and host variables. As a result, estimates of incidence and prevalence vary greatly depending on the population investigated, the date of cancer diagnosis, and the bleeding definitions used. The type and dosage of anticoagulant medication may also influence this risk. These problems underline the importance of a more holistic approach to bleeding in cancer care. Bleeding prevention should be prioritized in future cancer-related venous thromboembolism management regimens. To lower the clinical burden of cancer and enhance patient outcomes, we must advance our understanding of bleeding epidemiology.
Language: English
Subfield: Internal Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7154566267